Literature DB >> 14530817

Endobronchial large cell neuroendocrine carcinoma.

Mária Megyesi1, Mária Berta, Andras Khoor.   

Abstract

Lung tumors with neuroendocrine morphology include typical carcinoid, atypical carcinoid, large cell neuroendocrine carcinoma, and small cell carcinoma. The World Health Organization emphasizes the importance of mitotic count in differentiating these tumors. We studied the case of a 58-year-old male nonsmoker with recurrent pneumonia and an endobronchial mass, which was removed by right middle lobectomy. The patient was alive with no recurrent disease at 36-month follow-up. Histologically, the tumor showed well developed neuroendocrine morphology but contained up to 20 mitoses per 10 high-power fields and was therefore diagnosed as a large cell neuroendocrine carcinoma. However, several features, including the carcinoid-like morphology and endobronchial location of the tumor, absence of smoking history, and promising clinical course, were more characteristic of an atypical carcinoid than of a large cell neuroendocrine carcinoma. It may be necessary to redefine histologic criteria to allow a higher mitotic rate for classification as an atypical carcinoid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530817     DOI: 10.1007/bf03033739

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  7 in total

1.  Atypical carcinoid tumors of the lung.

Authors:  M G Arrigoni; L B Woolner; P E Bernatz
Journal:  J Thorac Cardiovasc Surg       Date:  1972-09       Impact factor: 5.209

2.  Large cell neuroendocrine carcinoma of the lung: clinical, CT, and pathologic findings in 11 patients.

Authors:  K J Jung; K S Lee; J Han; O J Kwon; J Kim; Y M Shim; T S Kim
Journal:  J Thorac Imaging       Date:  2001-07       Impact factor: 3.000

3.  Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung.

Authors:  C M Dresler; J H Ritter; G A Patterson; E Ross; M S Bailey; M R Wick
Journal:  Ann Thorac Surg       Date:  1997-01       Impact factor: 4.330

4.  Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.

Authors:  W D Travis; R I Linnoila; M G Tsokos; C L Hitchcock; G B Cutler; L Nieman; G Chrousos; H Pass; J Doppman
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

5.  Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases.

Authors:  Julien Mazières; Ghislaine Daste; Laurent Molinier; Jean Berjaud; Marcel Dahan; Martine Delsol; Pierre Carles; Alain Didier; Jean-Marc Bachaud
Journal:  Lung Cancer       Date:  2002-09       Impact factor: 5.705

6.  Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases.

Authors:  Hidefumi Takei; Hisao Asamura; Arafumi Maeshima; Kenji Suzuki; Haruhiko Kondo; Toshiro Niki; Tesshi Yamada; Ryosuke Tsuchiya; Yoshihiro Matsuno
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

7.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

  7 in total
  2 in total

1.  Roentgenological occult large-cell neuroendocrine carcinoma: Report of a long-term survivor.

Authors:  Mitsuhiro Kamiyoshihara; Takashi Ibe; Hitoshi Igai; Natsuko Kawatani; Atsushi Takise; Hideaki Itoh; Kimihiro Shimizu
Journal:  Respir Med Case Rep       Date:  2013-01-10

2.  Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.

Authors:  Natasha Rekhtman; Patrice Desmeules; Anna M Litvak; Maria C Pietanza; Maria Lauren Santos-Zabala; Ai Ni; Joseph Montecalvo; Jason C Chang; Amanda Beras; Isabel R Preeshagul; Joshua K Sabari; Charles M Rudin; Marc Ladanyi; David S Klimstra; William D Travis; Wei-Chu Lai
Journal:  Mod Pathol       Date:  2019-03-28       Impact factor: 7.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.